LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
TNYA
Tenaya Therapeutics, Inc.
There isn't enough reported data to score TNYA yet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
TNYA Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
TNYA's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
TNYA PE Valuation
TNYA has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
TNYA Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong decline | |
| -- | |
| Limited | |
| Low |
Analysts expect TNYA's revenue to decline, with its earnings and profitability holding steady. However, they disagree widely on these estimates.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over TNYA on earnings quality, reporting a profit while its opponent remains loss making.
TNYA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.46 | +$0.31 |
| Q2 2026 | -$0.50 | +$0.45 |
| Q1 2026 | -$0.44 | +$0.71 |
| Q4 2025 | -$0.59 | +$0.72 |
| Q3 2025 | -$0.77 | +$0.68 |
| Q2 2025 | -$0.95 | +$0.59 |
| Q1 2025 | -$1.15 | +$0.50 |
| Q4 2024 | -$1.31 | +$0.37 |
TNYA is still losing money, but far less than before: $0.46 per share over the past year, against $2.76 at its worst in late 2022.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY's revenue has grown year over year for 14 quarters in a row: $24.4B last quarter, up 39% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over TNYA on profitability, with a higher operating margin.
TNYA Quarterly Revenue
TNYA's revenue is growing: $2M last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -1153% | N/A |
| Q2 2026 | -3972% | N/A |
| Q1 2026 | -8918% | N/A |
LLY has the edge over TNYA on profitability, with a higher operating margin.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over TNYA on cash generation, producing positive trailing cash flow while its opponent burns cash.
TNYA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$17.7M | -$2.1M |
| Q2 2026 | -$3.7M | +$12M |
| Q1 2026 | -$19.2M | +$4.3M |
| Q4 2025 | -$14M | +$4.6M |
| Q3 2025 | -$15.6M | +$4.4M |
| Q2 2025 | -$15.8M | +$7.9M |
| Q1 2025 | -$23.5M | +$5.7M |
| Q4 2024 | -$18.6M | +$3.7M |
TNYA has burned cash in almost every quarter: −$55M over the past year, against −$73M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over TNYA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
TNYA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +8.4M shares |
| 1 year | +39% | +63.2M shares |
| 3 years | +208% | +153M shares |
| 5 years | +731% | +199M shares |
TNYA has 226M diluted shares, up 39% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2021 | — |
| Q3 2021 | $3,000 |
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | $1,000 |
| Q2 2020 | — |
| Q1 2020 | — |
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
TNYA Net Leverage
TNYA's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
TNYA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 30.0 | Oversold |
| Stochastic | 7.6 | Oversold |
TNYA's weekly RSI is 30 (oversold) and its Stochastic is 8 (oversold).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
TNYA PE vs Healthcare Sector
TNYA has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over TNYA on trend strength, trading above more of its moving averages.
TNYA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.45 | 22% below |
| 20 week MA | $0.62 | 44% below |
| 50 week MA | $0.71 | 51% below |
| 100 week MA | $0.86 | 59% below |
| 200 week MA | $2.28 | 85% below |
TNYA is in a downtrend: it's below all five of its weekly moving averages, and 85% below its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over TNYA on returns for 2026, with the stronger performance.
TNYA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $15.4 | $21.4 | +39% |
| 2022 | $21.4 | $1.84 | -91% |
| 2023 | $1.84 | $3.24 | +76% |
| 2024 | $3.24 | $1.50 | -54% |
| 2025 | $1.50 | $0.75 | -50% |
| 2026 YTD | $0.75 | $0.35 | -53% |
TNYA has finished lower in three of the last five years. It's down 53% so far in 2026.